University Of Tasmania

File(s) under permanent embargo

SARS-CoV-2 Vaccines: where are we now?

journal contribution
posted on 2023-05-21, 12:25 authored by Katie FlanaganKatie Flanagan, MacIntyre, CR, McIntyre, PB, Nelson, MR
The best and safest way to control the coronavirus disease 2019 (COVID-19) pandemic is by using vaccination to generate widespread immunity. The urgent need to develop safe and effective COVID-19 vaccines was met with unprecedented speed and action from the global community. There are now 289 vaccines in the development pipeline. More remarkably, there are 20 publicly available vaccines, and more than 3.3 billion doses of COVID-19 vaccines have been administered across 180 countries. This is just the beginning of our fight against the pandemic. Even at the current vaccination rate, it could take years to vaccinate the world's population; many high-income countries are focusing on their needs, whereas the poorer nations are waiting for vaccines. There is still much that we do not understand about immunity to this new disease, and we will have to contend with the emerging variants. In this commentary, we describe the current status of COVID-19 vaccine development and provide insights into how the development and approvals happened so quickly. We discuss the clinical trial data that led to rapid emergency use authorization and the many challenges of global rollout. We also comment on some of the key unanswered questions and future directions for COVID-19 vaccine development and deployment.


Publication title

Journal of Allergy and Clinical Immunology: In Practice










Tasmanian School of Medicine



Place of publication

New York

Repository Status

  • Restricted

Socio-economic Objectives

Urgent and critical care, and emergency medicine; Health protection and disaster response